Trials / Withdrawn
WithdrawnNCT02507947
SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
SPECTAmel is a standardized, quality-assured molecular screening platform for tumor characterization and storage of human biological material (HBM) for the purpose of integrating new biomarkers into clinical trials and optimizing access of patients to therapeutic biomarker-driven clinical trials. HBM and clinical/pathological data are collected from consenting patients.
Conditions
Timeline
- Primary completion
- 2030-01-01
- First posted
- 2015-07-24
- Last updated
- 2018-07-09
Source: ClinicalTrials.gov record NCT02507947. Inclusion in this directory is not an endorsement.